The FDA widens Anktiva's bladder-cancer approval to papillary-only tumours

The Food and Drug Administration broadened the approved use of nogapendekin alfa inbakicept-pmln, sold as Anktiva, on 14 October [s1]. Given alongside Bacillus Calmette-Guerin (BCG), the interleukin-15 receptor agonist can now be used in adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) whose disease is high-grade papillary-only, a group the agency says had no treatment approved specifically for it until now [s1][s2].

The change is narrow but clinically real. When early bladder cancer stops responding to BCG — the standard bladder-instilled immunotherapy — the textbook next step is to remove the bladder. Anktiva was first cleared in April 2024 for BCG-unresponsive disease carrying carcinoma in situ (CIS), with or without papillary tumours [s3]. Patients whose cancer was papillary only, without CIS, fell outside that wording. The October action closes that gap.

Non-muscle invasive bladder cancer is confined to the inner lining of the bladder and has not grown into the muscle wall. It is treatable, often for years, without removing the organ — which is why bladder-sparing options matter so much here. BCG, a bladder-instilled form of the tuberculosis vaccine, is the mainstay after the tumour is resected, and most patients respond. The hard cases are those whose cancer comes back or persists despite adequate BCG: that is what "BCG-unresponsive" means, and it is the point at which the choice has traditionally narrowed to major surgery. A drug that can be dripped into the bladder instead of cutting it out is attractive precisely because the alternative is so consequential.

An approval built on extrapolation, not a new trial

What makes this decision unusual is how the agency reached it. The FDA did not require a fresh study in papillary-only patients. Instead it relied on the original dataset and a biological argument [s1].

The efficacy evidence remains Cohort A of the single-arm QUILT-3.032 trial (NCT03022825), which treated 77 patients with BCG-unresponsive high-risk NMIBC with CIS, with or without Ta or T1 papillary disease [s1]. The complete response rate — assessed by cystoscopy, urine cytology and biopsy — was 62% (95% CI 51 to 73) [s1]. Among those who responded, 58% maintained the response for at least 12 months and 40% for at least 24 months [s1].

From there, the agency reasoned across tumour types. High-grade papillary tumours and CIS have different architectural growth patterns, it noted, but both are aggressive urothelial carcinomas, and in the BCG-unresponsive setting both carry a high risk of recurrence and progression [s1]. On that basis the FDA concluded that the demonstrated benefit in CIS-containing disease could be extrapolated to high-grade papillary-only disease, and expanded the indication accordingly [s1].

Readers should see that reasoning clearly. The papillary-only population was not measured directly; its approval is inferred. That is a legitimate regulatory tool, but it is a weaker form of evidence than a trial that enrolled and followed the actual group being treated, and the complete-response figures above describe the CIS-containing cohort, not papillary-only patients.

How it is given

Anktiva is instilled into the bladder, not infused or injected systemically [s1]. Induction is 400 micrograms with BCG once weekly for six weeks, with a second induction course permitted if residual CIS or high-grade Ta tumours are present at month three [s1]. Maintenance courses of three weekly instillations follow at months 4, 7, 10, 13 and 19, and patients free of high-grade disease at month 25 or later may receive further courses at months 25, 31 and 37 [s1]. Treatment stops for disease that persists after a second induction, for recurrence or progression, or for unacceptable toxicity, to a maximum duration of 37 months [s1].

What to watch

Two things. First, whether real-world outcomes in papillary-only patients track the CIS results the approval leaned on — the question the extrapolation leaves open, and one only post-marketing follow-up can answer. Second, durability: a complete response that lasts two years in 40% of responders is meaningful in a disease whose alternative is cystectomy, but it also means most responses were not documented past that mark, and bladder preservation is only a benefit for as long as the cancer stays away [s1].

Red flags: visible blood in the urine, or new urinary urgency or pain, in anyone treated or monitored for bladder cancer warrants prompt urological review rather than watchful waiting. This article describes regulatory news and is not medical advice. Decisions about bladder-cancer treatment are for patients and their treating clinicians.